<DOC>
	<DOCNO>NCT02064907</DOCNO>
	<brief_summary>The purpose study ass pharmacokinetics ( PK ) Pharmacodynamics ( PD ) dexlansoprazole delayed-release orally disintegrate ( OD ) tablet administer tongue swallow without water .</brief_summary>
	<brief_title>Bioavailability , Safety , Pharmacodynamics Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Healthy Participants</brief_title>
	<detailed_description>The drug test study call dexlansoprazole . Dexlansoprazole test see two different form medication react way human body . This study look biological sample people take orally disintegrate tablet dexlansoprazole compare swallow capsule dexlansoprazole . The study enroll approximately 52 patient . Participants randomly assign ( chance , like flip coin ) one two treatment group . Both treatment group receive form dexlansoprazole different time period : - Two dexlansoprazole 30 mg orally disintegrate tablet 5 day - One dexlansoprazole 60 mg capsule 5 day . All participant ask take two tablet one capsule time day throughout treatment period study . This single-centre trial conduct United States . Participants make 3 visit clinic include two 6-day period confinement clinic , contact telephone 5 10 day last dose study drug follow-up assessment . The overall time participate study 57 day .</detailed_description>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is healthy adult male female participant Checkin ( Day 1 Period 1 ) . 4 . Is age 18 55 year inclusive , Screening first dose day ( Day 1 Period 1 ) . 5 . Weighs least 50 kg body mass index ( BMI ) 18.0 30.0 kg/m^2 , inclusive Screening . 6 . If male participant nonsterilized sexually active female partner childbearing potential , agree use adequate contraception signing informed consent form throughout duration study 30 day last dose study drug . 7 . If female participant childbearing potential sexually active nonsterilized male partner , agree use routinely adequate contraception signing inform consent throughout duration study 30 day follow last dose study drug . Female participant childbearing potential must negative serum pregnancy test Screening Checkin ( Day 1 Period 1 ) must nurse . 8 . Is good health determine physician base medical history , vital sign , electrocardiogram ( ECG ) physical examination finding Screening Checkin ( Day 1 Period 1 ) , applicable . 9 . Has clinical chemistry , hematology , complete urinalysis ( fast least 10 hour ) Screening Checkin ( Day 1 Period 1 ) result within reference range test laboratory unless range result deem clinically significant investigator . 1 . Has receive investigational compound within 30 day prior Checkin ( Day 1 Period 1 ) . 2 . Has ever receive dexlansoprazole previous clinical study receive dexlansoprazole lansoprazole therapeutic agent within 28 day prior Checkin ( Day 1 Period 1 ) . 3 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has uncontrolled , clinically significant hematologic , neurologic , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine , psychiatric disorder abnormality ( disease study ) , may impact ability participant participate potentially confound study result . 5 . Has know hypersensitivity component formulation dexlansoprazole delayedrelease orally disintegrate ( OD ) tablets participant know hypersensitivity component formulation dexlansoprazole delayedrelease capsule drug mechanism action ( include esomeprazole , lansoprazole , omeprazole , pantoprazole , rabeprazole ) . 6 . Consumed alcohol drug abuse within 7 day prior checkin ( Day 1 Period 1 ) , positive test result alcohol drug abuse Screening Checkin ( Day 1 Period 1 ) , unwilling abstain alcohol drug abuse throughout study . 7 . Has receive know hepatic renal clearance alter agent ( eg , erythromycin , cimetidine , barbiturate , phenothiazine , fluvoxamine , etc . ) within 28 day prior Day 1 Period 1 . 8 . Has acute , clinically significant illness within 30 day prior Day 1 Period 1 . 9 . Has history drug abuse ( define illicit drug use ) history alcohol abuse ( define alcohol consumption exceed 14 unit per week ) within 1 year prior Screening Visit unwilling agree abstain alcohol drug throughout study . 10 . With exception acetaminophen , participant take excluded medication , supplement food product . 11 . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 12 . If male , participant intend impregnate others donate sperm course study 30 day thereafter . 13 . Has consume product contain caffeine and/or xanthine within 72 hour prior Checkin ( Day 1 Period 1 ) unwilling abstain product duration study . 14 . Has current recent ( within 6 month screen ) gastrointestinal disease include esophageal reflux , frequent ( per week ) occurrence heartburn , history malabsorption ( ie , celiac disease , biliary atresia , cholestasis ) , peptic ulcer disease , surgical intervention [ eg , cholecystectomy , gastric bypass ) , would expect influence absorption drug . 15 . Has history cancer , except basal cell carcinoma skin remission least 5 year prior Day 1 Period 1 . 16 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) , Screening know history human immunodeficiency virus infection . 17 . Used nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 28 day prior Checkin ( Day 1 Period 1 ) , positive cotinine test Screening Checkin ( Day 1 Period 1 ) unwilling abstain product duration study . 18 . Has poor peripheral venous access . 19 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 56 day prior Day 1 Period 1 . 20 . Has Screening Checkin ( Day 1 Period 1 ) abnormal ( clinically significant ) ECG . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator medically qualify subinvestigator . 21 . Has abnormal Screening Day 1 laboratory value suggest clinically significant underlying disease participant follow lab abnormality : creatinine &gt; 1.5 mg/dL , alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 2.5Ã— upper limit normal ( ULN ) , total bilirubin &gt; 2.0 mg/dL . 22 . Has positive breath test result H pylorus Screening . 23 . Has history disorder metabolize phenylalanine ( phenylketonuria ) . 24 . Can tolerate placement pH probe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>